Page 1

LifeLines For the Life Science Community

9

Public Policy: Building Momentum

14

Accelerating The Promise of L.A.

24

To Listen Means to Know

Biocom, Beyond Borders VOLUME 25, ISSUE 2 S u m m e r 2 0 1 6


ONE TEAM. ONE FOCUS.

www.sdlifesciences.com

LILLY

300,000 SF Tenant Representation

DEXCOM, INC.

518,000 SF Tenant Representation

ALTHEADX

70,000 SF Tenant Representation

REAL ESTATE EXPERTS FOR THE LIFE SCIENCES INDUSTRY

BRENT JACOBS

brent.jacobs@cushwake.com CA License No. 791657

GREG BISCONTI

greg.bisconti@cushwake.com CA License No. 1167920

TED JACOBS

ted.jacobs@cushwake.com CA License No. 1855220

(858) 452-6500

ARCTURUS THERAPEUTICS

SYNTHETIC GENOMICS

BIOCOM

CRINETICS PHARMACEUTICALS

NITTO DENKO

AJINOMOTO ALTHEA

10,000 SF Tenant Representation

6,000 SF Tenant Representation

75,000 SF Tenant Representation

25,000 SF Tenant Representation

11,000 SF Tenant Representation

56,700 SF Tenant Representation


IN THIS ISSUE 2 Cover Story: Biocom, Beyond Borders 9 Public Policy: Building Momentum 10 Biocom Launches the Catalyst Awards 12 Guest: Accelerating Company Growth—One Bench at a Time

14 Biocom L.A.: Accelerating The Promise of L.A. 17 Biocom Institute: People: The Key to Accelerating Life Science Success

18 Science Festival: STEM in the Community Members in Action: Biocom institute Festival 19-22

of Science & Engineering San Diego, Biocom Events, Annual Charity Golf Tournament

24 Biocom Membership: To Listen Means to Know 27 Purchasing Group: Accelerating Growth & Changing the Game

28 Biocom in the News 32 Biocom Strong: Tioga Research 33 Premium Member Spotlights:

Ajinomoto Pharmaceuticals, Cooley, Office Depot

34 Biocom Board and Committees 35 Biocom Membership E D I TO R : Jennifer Landress CO P Y E D I TO R : Julie Ames DESIGN & LAYOUT: Arlene Arreola VOLUME 25, ISSUE 2

Biocom, a member-driven organization, is here to assist life science companies like yours to fulfill your most ambitious goals. We can help your company with saving money, advocacy, increased visibility, networking opportunities, capital development and workforce development.

WELCOME By Joe Panetta, President and CEO, Biocom

LOOKING TO THE FUTURE

Welcome to the summer 2016 edition of LifeLines, our periodic magazine highlighting the collaborative achievements of Biocom and our more than 750 member companies and organizations throughout the California life science community and beyond. This issue’s cover story discusses our industry presence and initiatives that will advance Biocom’s mission of accelerating life science success on local, regional, state, national and global levels. As California’s largest and longest-established life science association, we are well-aware that our model of success is driven by an understanding of the unique strengths of local clusters and the power and opportunities that can arise when they work together. In this regard, we are pleased to unveil our story on the promise of Los Angeles, where we have opened an office under the leadership of Executive Director Dina Lozofsky. Dina discusses the opportunities that Biocom brings to life science companies in L.A. as well as the potential synergies between the L.A. and San Diego life science communities. Also relative to our vision, you will read about our exceptional new lab supplies contract negotiated by the Biocom Purchasing Group, an offering that will greatly extend the purchasing power and dollar savings of our members throughout California. On the important advocacy front, you will read about how a membership that is powerfully represented by companies from the Bay Area to the Mexican border yields even stronger ties with elected officials in Washington on issues such as drug pricing legislation, funding for initiatives in precision medicine, and bills that accelerate innovation. As a recent participant in the BIO Annual Legislative Day on Capitol Hill, I was pleased to be able to meet with Congressional representatives from Districts throughout Southern California and to join with our members in presenting the opportunities and challenges faced by our industry. I often say that our life science workforce—those who conduct the research and manage the organizations that deliver life-saving products—are our most important asset. In this edition, we once again present our California Life Science Demand Report, a partnership effort led by our Biocom Institute, along with the California Life Science Institute. Keeping on the theme of our life science talent, Sr. VP and COO Jen Landress discusses the new Catalyst Awards. We are partnering with the San Diego Venture Group to identify the most inspiring and driven academics, entrepreneurs, investors, corporate leaders and business advisers who are making their mark in life sciences in our region before their 40th birthday. Jen asks individuals to nominate those in the community who are change agents and are sparking innovation in the industry. Having completed one of the most successful membership years in our association’s history, we are hard at work this year looking to deliver greater value to our companies, while continuing to thoughtfully build our presence throughout California. Our story on membership talks about how organizationally we actively listen to our members and highlights some examples of programs that are member-driven. One of our fastest growing sectors is contract and consulting services, which plays a critical role in launching companies. Susie Harborth writes about our engagement with her company, Bio-Labs San Diego, a new incubator launching this month. Susie brings previous experience and successes in Boston and North Carolina to the San Diego life science scene. I hope you enjoy the stories and people featured in this edition of LifeLines, and I hope to see you, our valuable members, in my travels throughout California in the future!

WWW.BIOCOM.ORG Biocom LifeLines Summer 2016

1


COVER STORY

By Kelly Quigley, Canale Communications

Biocom, Beyond Borders

Come with us for an inside look at Biocom’s strategy to expand its reach to other cities, states and countries—all in the name of robust economic development for the San Diego life science industry. It wasn’t all that long ago that business—and life, in general— was a mostly local endeavor. That was before the days of convenient international air travel and ever-present internet, which together have shaped a highly interconnected business environment and redefined the way that nearly every industry operates. Life sciences included. Aided by these and an array of other new technologies, the world has become a more intimate place. Far-away countries have become our new neighbors. Companies half-way across the globe have become partners, suppliers and allies. While San Diego embraces a tight-knit and remarkably collegial life science community, its companies and research institutes are highly engaged in addressing global needs—from conquering malaria to developing renewable chemicals for eco-friendly manufacturing all over the world.

2

Biocom LifeLines Summer 2016

Indeed, it’s nearly impossible to find any life science company in San Diego that isn’t seeking to overcome a global-scale challenge of some sort. We are a city of big ideas, and our companies are more than a little bit determined to turn those ideas into real, commercial solutions. Biocom is at the heart of this, keeping the engine churning not just locally but also in our nation’s capital and as far away as Japan. To work on behalf of more than 750 life science companies means to enable connections around the world and ensure that the business climate for our industry is thriving in every sense. Such is the impetus behind Biocom’s steady geographic expansion over the last five years. Here, we take a look at the three unique geographic areas in which Biocom has strategically launched operations, and why these areas are so critical to the growth of the San Diego life science industry.


COVER STORY

+1

Los Angeles What is a San Diego-based industry organization doing in Los Angeles? Helping a high-potential market get organized, for starters. Biocom in April established an office in downtown Los Angeles, and hired a seasoned industry pro, Dina Lozofsky, as the executive director. Los Angeles has a lot going for it, but would benefit from a more cohesive industry voice – leading to potentially greater economic growth across the region. Despite the city’s global trade prowess and convenient international access, not to mention world-renowned scientific and medical centers (including the University of California, Los Angeles and CedarsSinai Medical Center), too many of the innovative ideas that are born in the area end up in other, more established markets. Lozofsky already is working to change that, helping to ensure that discoveries created in Southern California stay here. She also wants to keep promising young talent from moving away, connecting them with rewarding positions at one of the region’s many life science companies. By unifying the growth of the Southern California life science community, while customizing programs for each city’s unique ecosystem, the goal is to become an even more competitive regional force on a national and global scale.

+1

Washington With the job of representing one of the country’s top-three concentrations of life science companies, Biocom has an enormous stake in the outcome of federal policymaking. In January of 2013, after more than a year of careful planning, Biocom established a full-time presence in Washington, D.C. The decision has allowed the organization to elevate public policy efforts to a higher level than was possible before and to collaborate closely with BIO, the international organization for life sciences. Located just blocks from the Washington Monument, Biocom’s D.C. operations have forged long-lasting relationships with both policymakers and regulators in the nation’s capitol, where Biocom continues to advocate for a more efficient Food and Drug Administration, a robust Medicare reimbursement system, adequate funding for the National Institutes of Health, and innovation-friendly tax and trade policies, among other things. When it comes to interacting with government officials, there’s no amount of internet that will ever beat face-to-face communications.

+1

Tokyo It all started with Japan Airlines’ announcement in 2013 that it would begin a direct flight to Tokyo. Biocom had long been making inroads into the Asian life science marketplace, but the easy direct flight is ultimately what paved the way for a series of business deals that have significantly boosted Japan’s pharmaceutical presence in San Diego. As of 2014, Biocom operates a fulltime satellite office in Tokyo, where a small staff meets with companies and investors interested in San Diego’s talent and U.S. pharmaceutical industry ties. Biocom president and CEO Joe Panetta makes trips to the Tokyo office once or twice per year, with each trip consistently resulting in new partnerships or liaisons with Southern California-based companies. The ultimate goal: Establish Biocom as the leading portal to Japan for California life sciences companies. As more Asian companies do business here, and as local companies learn of opportunities in Japan, the sector’s economic impact will grow, creating high-paying life science jobs and fueling additional industry expansion.

Biocom LifeLines Summer 2016

3


[

]

Experience How Everything We Do Has A Single Focus - Your Success

Providing aaest services to a wide variety of public companies, early-stage and growing private companies. We are one of the leading providers of accounnng services to Southern California’s Technology & Life Sciences industries - focusing on private companies preparing to go public or be acquired.

www.mhmcpa.com | 858.795.2000 Contact David Diamond Technology & Life Sciences Praccce Leader ddiamond@cbiz.com Mayer Hoffman McCann P.C. is an independent CPA firm providing audit, review and other aaest services, and works closely with CBIZ, a business consullng, tax and financial services provider.


COVER STORY San Diego: The Ultimate Home Base It’s not enough anymore to think within the borders of your own city or region. We work in a highly global industry, and we must be proactive in forging new connections both among local life science players and with companies around the world. As Biocom enters its third decade of industry leadership, its mission to build a collaborative, supportive and knowledge-sharing environment will increasingly involve activities that span the globe. But no matter how much we embrace international or cross-country travel, most San Diegans will agree: there is no place like home. San Diego’s World-Wide Reputation San Diego is doing amazing things in its beautiful corner of the world, grabbing international headlines for various impressive elements of its life science industry. Within the last several months, San Diego has been globally recognized for… Genomics Innovation San Diego is known as the genomics capital of the world. And while Craig Venter’s unmistakable presence in our city certainly plays a role in that, there’s a growing body of additional evidence to back up the extraordinary title. Case in point: The doctor who just earned the Guinness World Records designation for fastest-ever genetic diagnosis is based right here in San Diego. Dr. Stephen Kingsmore, M.D., president and CEO of Rady Children’s Institute for Genomic Medicine, was honored for the record-breaking achievement at a press conference on April 25, which also happened to be National DNA Day. He successfully diagnosed critically ill newborns in just 26 hours, a feat enabled by two other San Diego genomic players: Illumina Inc., which developed the gene-sequencing equipment, and Edico Genome Inc., which provided the genomic data-crunching computer chip known as DRAGEN. Patent Intensity The Organization for Economic Cooperation and Development, based in Paris, has named San Diego the most innovative city in the U.S. and the secondmost innovative in the world based on its volume of patents issued. “Patent intensity” is a common measure of inventiveness, and it makes sense that Continued Pg 6

Biocom on the Map From Local to Global

1995

2001 The Biotechnology Industry Organization (BIO) International Convention is held in San Diego for the first time, putting America’s Finest City on the global map not just for its beaches, but for its life science brawn. In selecting San Diego as its convention host, BIO cited the city’s robust base of 2,500-plus life science companies and research institutes. San Diego is now in the regular rotation of BIO host cities.

Biocom is founded, bringing together the San Diego life science industry to address a highly local issue: the water shortage. Soon, the organization was tackling other local, state and eventually federal issues that influence the life science business climate.

2013 Biocom opens an office in Washington,D.C., establishing the organization’s first permanent presence in the nation’s capital. The mission: manage and implement Biocom’s federal policy agenda, and proactively lobby federal officials to advance the interests of Biocom’s members.

2014 Biocom launches its Tokyo office, with the goal of building a bridge between life science companies in Japan and Southern California and creating greater awareness of opportunities in Japan. The initiative has resulted in the development of several key relationships between Biocom and major life science entities in Japan.

2016 New office opens in Los Angeles, solidifying a connection that has long existed between the complementary life science ecosystems of San Diego and L.A.

Biocom LifeLines Summer 2016

5


COVER STORY San Diego tops the list, with high concentration of biomedical research institutes and life science companies. According to the OECD report, San Diego produces 8.9 patents for every 10,000 residents. The ranking reinforces San Diego’s reputation for tackling difficult, early-stage science and providing the innovation that fuels new company formation. Other U.S. cities on the top 15 list included Boston, Minneapolis and Seattle. Far-Reaching Science Call it the San Diego ripple effect. Scientists working at our region’s many research institutes—from University of California, San Diego to The Salk Institute of Biological Studies—are churning out discoveries that impact the work of many, many other researchers around the globe. In an annual raking published earlier this year, Thomson-Reuters said San Diego is home to 41 of the most influential researchers in the world. The scholars on the list were highly cited by their peers during the 10-year period from 2003 to 2013, indicating a strong impact and influence on

others’ work. Among the noted scientists is Phil Baran, an organic chemist at The Scripps Research Institute who is transforming marine molecules into cancer-fighting drugs through his work with San Diego-based Sirenas Marine Discovery Inc. Kelly Quigley is a science journalist who serves as content director at San Diego-based Canale Communications, which specializes in public relations, investor relations and visual communications for life science companies.


ChemDiv Metabolic

Oncology

The chemistry of cures

Inflammation

SM

Infection

CNS

Cardiovascular

NEW PRODUCT DEVELOPMENT & MARKET ACCESS Growing Demand for New Medicines

THE PROBLEM

EMERGING MARKETS PROJECTED AVERAGE MEDICINES SPENDING GROWTH

CEE 49.6%

Saudi Arabia, Turkey, Algeria, Egypt, Nigeria China, Thailand, Vietnam, Philippines, Indonesia, Pakistan, India, Bangladesh

LA 38.4%

Russia, Poland, Kazakhstan Brazil, Chile, Argentina, Columbia, Mexico Source: IMS Health, Market Prognosis, September 2015; IMS Institute for Healthcare Informatics, October 2015

THE SOLUTION

MENA 64.8%

Asia 58%

2016-2020

2x Faster Development and Registration NEW COMBINATIONS NEW FORMULATIONS FIRST GENERICS

2x 2x

THE PATH

14

Original Products

ORIGINAL DRUGS

6 Market Launches in 2015 9

First Generics

9

Drug Combinations

4

Drug Formulations

For more information visit www.chemdiv.com/pharmatech-services

8

Generics


PUBLIC POLICY

By Jimmy Jackson, Senior Vice President of Public Policy, Biocom

Public Policy: Building Momentum This is definitely a year of momentum for Biocom’s Public Policy department. With a new office in Los Angeles, we will be building stronger ties with elected officials from the greater Los Angeles area at all levels of government. At the federal and state level, this is an opportunity to bring together members of both parties to support one of Southern California’s most critical economic drivers. These elected officials have expressed great enthusiasm for Biocom’s already-formed partnerships with established members of the economic fabric of the area, such as the Los Angeles Economic Development Corporation, and we are certainly excited at the possibilities before us. As you undoubtedly have heard, a topic of much discussion this year is drug pricing. Unfortunately, the actions of a few outlier companies have allowed our opponents to make sweeping (and inaccurate) portrayals of the industry and opened the door to hyperbole and demagoguery by some. Biocom will continue to be active and keep you informed as Congressional hearings continue on this issue. As we have discussed in past LifeLines, at the state level, California voters will vote on a misleading November state drug purchasing initiative that offers what is almost certainly an unworkable program. Please keep an eye out for updates on this measure in the Biocommunique as we move closer to the election. Biocom President and CEO Joe Panetta, in his capacity as chair of the California Biotechnology Foundation (CBF), recently penned an op-ed which was published in the Sacramento Bee discussing not only the costs of developing breakthrough therapies, but also the life-saving and life-changing benefits to patients. In May, Biocom joined with fifteen other state and regional life science associations to host a Capitol Hill briefing on the value of biomedical innovation. Biocom will continue to engage with the CBF and other strategic partners to advance meaningful conversation on this issue. Meanwhile, the Senate is working on a companion bill to the House of Representatives 21st Century Cures Act, which passed that body last year. In contrast to the House’s approach, the Senate Health Committee has been considering component bills individually, allowing some of them to move faster through the legislative process, such as legislation to make the Zika virus eligible for the Tropical Disease Priority Review Voucher Program, which was signed into law in April. Unlike the 21st Century Cures Act, however, the Senate Innovation Initiative does not address reimbursement issues and does not currently provide mandatory funding for the National Institutes of Health (NIH), both matters being top priorities for Biocom.

Another issue which is getting significant attention in Washington is the President’s Precision Medicine Initiative. As Southern California is well positioned to be a global leader in this developing field, Biocom will be hosting a Capitol Hill briefing on this issue on June 22nd, followed by a reception by Biocom, the Healthcare Institute of New Jersey (HINJ), and the Congressional Life Science Caucus, co-chaired by San Diego’s own Congressman Scott Peters. On the state level, we look forward to supporting the advance of bills to accelerate innovation and entrepreneurship coming from University of California campuses, help give patients a more predictable path through which to get approval for nonformulary drugs, and introduce the practice of comprehensive medication management (through which careful review of all medications a patient is prescribed is done at regular intervals to catch potential drug interactions and duplications) for Medi-Cal patients. The industry also continues to address bills requiring public release of proprietary data, and has temporarily forestalled yet another attempt to saddle the industry with all financial responsibility for sharps disposal. As we continue forward into the legislative year, Biocom will remain deeply engaged on these and other issues of interest to life science companies. On the local and regulatory front, Biocom is actively engaged with our member companies impacted by a court decision (“Newhall”) which has had the unintended consequence of delaying building permits throughout the state as cities scramble to adopt rules pertaining to local Climate Action Plans per the decision. We also are creating some of our best programming ever through both the Biocom Facilities Committee and the Environmental Health and Safety Committee, as we continue to serve the needs of our members at all levels.

Jimmy Jackson is the Senior Vice President of Public Policy for Biocom. He oversees government affairs and public policy for the organization.

Biocom LifeLines Summer 2016

9


CAPITAL DEVELOPMENT

By Jennifer Landress, Senior VP and COO

Biocom Launches the Catalyst Awards The future of The Science of Life will be profoundly impacted by groundbreaking science driven by the Southern California cluster. The region leads the world in areas such as Digital Health, Personalized Medicine and Brain Science, and has become the undisputable global center for Genomics. Southern California companies are making daily breakthroughs in the fields that impact human health in significant ways, including unearthing important clues as to the cause of and potential treatments for Alzheimer’s and other serious diseases and discovering mechanisms in the body and mind that were previously unknown. The confluence of science talent, experienced leadership, worldclass research and capital are propelling momentum in Southern California that is accelerating discovery and development of technologies to improve the human experience and our well-being. Who are the rising stars in this rapidly growing life science ecosystem? Who are the ones paving the way that should be recognized for their efforts? We need your help to find them. Biocom is pleased to announce the first-ever Catalyst Awards, which annually will honor up-and-coming leaders who are sparking innovation in Southern California’s life science industry. Biocom is uniting with the San Diego Venture Group (SDVG) to identify the most inspiring and driven academics, entrepreneurs, investors, corporate leaders and business advisers who are making their mark in life sciences in our region before their 40th birthday. Honorees will be highlighted in the next edition of the Biocom LifeLines magazine, on a web site dedicated to the Biocom Catalyst Awards, and celebrated at the SDVG annual Luminaries Dinner in the fall. So look around you: who are the young leaders of your industry? Then visit www.lifescience-catalyst.com for instructions on how to nominate someone you know—or even yourself. The nomination process is simple and fast. The submission deadline is July 15th.

We will honor standouts from: • Biotechnology (healthcare, industrial, environmental) • Pharmaceuticals • Genomics • Medical Devices • Diagnostics • Digital Health • Universities and Research Institutes • Business Consulting • Venture Capital • Clinical and development www.lifescience-catalyst.com

Jennifer Landress is Senior Vice President and COO and heads the Capital Development Initiative for Biocom.

10

Biocom LifeLines Summer 2016


GUEST

By Susie Harborth, General Partner, CFO, Bio Innovation Capital

Accelerating Company Growth—One Bench at a Time As every startup entrepreneur knows, launching a company is not an easy task. Besides negotiating the license agreement, finding capital and building out the team, there is the whole world of finding lab space and purchasing capital equipment— which oftentimes happens only after funding is secured and the milestone clock starts ticking. Given the long task list, and limited resources, early stage companies face major roadblocks before they are able to create valuable inflection points. There are many models of venture acceleration which are helping to change the current landscape for start-ups but we can always do more in order to keep innovation fresh and thriving. As entrepreneurs and investors ourselves, we have been through this many times and know first-hand the pain points that startups face. BioLabs San Diego, alongside our Founding Partner, Biocom, was designed to be the premier coworking space for life science start-ups—a unique place in which to test, develop and grow game-changing ideas. We wanted to build a community that enabled small companies to launch, while being surrounded by a wealth of resources to accelerate company formation and growth. Our success in building similar facilities in other geographies, including San Francisco, Cambridge and Raleigh-Durham, North Carolina, has given us strong insights to the best practices when it comes to how companies at their earliest stages develop and grow. Some of the unique features of BioLabs include: ARCHITECTURAL FEATURES Our workspaces are designed with smaller organizations in mind, in an all-inclusive model comprising open laboratories with bench spaces, conference rooms, event space, café with coffee and health snacks, and day lockers for individuals’ belongings. COWORKING OFFICE SPACE Work side by side with like-minded and dynamic entrepreneurial scientists and founders, as well as biotech and pharmaceutical partners. RESEARCH EQUIPMENT Best-in-class and fully supported PCR machines, freezers and refrigerators, plate readers, microscopes, centrifuges, shakers and vortexers, gel imagers, flow cytometry and more. NETWORKING + SOCIAL EVENTS BioLabs tenants will also be members Biocom and will have immediate access to member exclusive benefits and events. INDUSTRY CONNECTIONS Our tenant companies have access to leading industry partners— from big pharma to life science organizations as well as those with legal and regulatory expertise. Over the past decade, work spaces have transitioned from traditional offices to creative, collaborative environments. In

12

Biocom LifeLines Summer 2016

addition, there is a momentum towards coworking spaces, both for single tenants who occupy a campus to smaller incubator-type facilities. This has been exemplified in the tech ecosystem with companies such as Google, Pixar and Facebook who provide their employees with workspaces designed to “move people.” The biotech industry is also adopting this work style—opting for maximum “human collision” to happen in cafes and hallways. This open environment is encouraging more ad hoc meetings and collaboration, albeit within a different culture. However as a startup, how do you create a company culture, foster innovation and accelerate with one or two employees? More and more, biotech entrepreneurs we have surveyed desire to be with other like-minded peers, but in an environment that understands the needs of early stage companies. San Diego has a wealth of resources for early stage entrepreneurs, including access to world-class research institutions, a skilled and diverse workforce, and an ecosystem supported by leading industry partners. Despite the collaborative environment for startups in Southern California, most of the shared lab spaces lack elements of support that are crucial to success. As a biotech or life science company looking to meet milestones and make research advances, the ability to access suitable lab space becomes a major roadblock. There is abundant vacant space, but the availability of flexible, fully-equipped space is scarce. The main need for early stage innovators is flexibility, to expand and contract as business needs evolve—and traditional office and lab spaces are not built for dynamic and changing business objectives. At BioLabs San Diego, companies can start with renting a single bench and expand as needed. The space is designed for the smaller company, but with the benefits oftentimes found only in progressive, large companies. Besides lab bench and access to equipment, BioLabs facilities bring intangible benefits to users including connections to capital, introductions to industry partners as well as the peer learning that occurs among our network of spaces in other leading innovation hubs. If you are an entrepreneur with an early stage company, take a tour of BioLabs and find a space to work on your life’s passion. Details on tours and availability can be found on our website: www.biolabs.io

Susie Harborth is currently General Partner and CFO at BioInnovation Capital and Managing Director/Co-Founder of BioLabs San Diego


Introducing Our New Rabbit mAb Service:

Single Plasma Cell Cloning

Flow Cytometry

Light

2

70-105 Days

Phase III Cloning & Expression • Amplify heavy & light chains • Clone into expression vector

The ProSci Advantage Hybridoma

Phage Display

Single B Cell Cloning

Single Plasma Cell Cloning

B Cells

B Cells

B Cells

Plasma Cells

≤ 1% Plasma Cells

≤ 1% Plasma Cells

≤ 1% Plasma Cells

100% Plasma Cells

Screening Time

12 Weeks

6 Weeks

3 Weeks

3 Weeks

mAb Diversity

Medium

Low

High

High

Start Material Efficiency

Days

Days

Phase II Plasma Cell Isolation • Isolate plasma cells from 1 rabbit • Plate 1 cell per well

11

7

Days

Phase I Immunization • 3 rabbits • ELISA screening

Heavy

Sort single plasma cells into wells

Phase IV Selection & Delivery • Sequence of positive clones • ELISA report • 200 μg purified antibody for up to 5 clones

Visit our Website to Learn More prosci-inc.com/rabbit-mabs

Custom

Your Antibody Experts • >18,000 custom antibody projects completed since 1998 • In-house labs & 150,000 ft2 of animal facilities on 27 acres • USDA licensed & NIH/OLAW assured facilities

prosci-inc.com | info@prosci-inc.com | (858) 513 2638 © 2016-1 ProSci Incorporated. All rights reserved.

TM

ProSci


BIOCOM L.A.

By Dina Lozofsky, Executive Director, Biocom L.A.

Accelerating The Promise of L.A. There is significant unrealized potential in the life sciences community in the greater Los Angeles area. The region has all the building blocks needed to foster and grow a thriving life science powerhouse on par with the best life science clusters in the world. It has multiple leading universities and research hospitals, which annually generate world class technology and talent. It already has a strong base of life science companies, large and small, and possesses the infrastructure to support growth in this sector, including an international airport. Having worked in Los Angeles most of my professional life, I have a great appreciation for its strengths, particularly when it comes to the region’s ongoing research. One of the factors critical to the growth of this cluster is to attract more venture capital into the area, which depends upon a better understanding outside of the region regarding the breadth of opportunity in technology and talent that is generated annually. The backbone of value creation and growth is strong intellectual property and talent development. In 2015, for example, the area’s research institutes and universities attracted almost $1 billion dollars in NIH funding, reflecting the quality of the research being performed here. Consequently, the local universities and research hospitals are ready, willing and able to work with industry to spin out their technologies, into established companies or startups. Some highlights from the region: •

14

UCLA has 131 active startups with licensed intellectual property. 79% of those are in the life sciences, including therapeutics, medical devices, diagnostics, research tools, and digital health. This spring, the Cedars Sinai and TechStars launched the first class in their Techstars Healthcare Accelerator, focused on transforming innovation in health and healthcare delivery. Caltech, long recognized as a powerhouse in high tech, is generating more life science related IP than ever before. In ten years time, the percentage of biomedical technologies in its portfolio went from 30% to 60%. The Center for Innovation at Children’s Hospital Los Angeles supports innovators from CHLA, its academic partner USC, and from across the United States, through the Consortium for Technology and Innovation in Pediatrics (CTIP), an FDAfunded accelerator supporting the commercialization of pediatric medical technologies.

Biocom LifeLines Summer 2016

The Argus II Retinal Prosthesis system, the first FDAapproved implanted device to reestablish some sight in blind patients, was for the first time implanted in both eyes in a patient last year. Argus II, manufactured by LA areabased Second Sight, is based on technology developed and licensed by USC. The building blocks are in place. The potential in Los Angeles can be realized with targeted support that will push it to the next level—the kind of support that Biocom has developed over two decades to create a thriving San Diego life science industry. What we need now is to communicate to the world the value of the existing life sciences in this area, connect existing companies with startups and new technologies to form a cohesive collaborative community, and accelerate growth in a way that benefits everyone from the research institutes to government to the local established life sciences companies, all of whom have been working and innovating in the area for decades. And that is the promise in L.A. ...stay tuned for updates. If you’d like to learn more about how to be a part of building this life sciences cluster, please visit our Los Angeles office website at www.biocomla.org or contact me directly.

Dina Lozofsky is the Executive Director of the Biocom Los Angeles office.


#RadyMade Dermatologist

Dir. Healthcare Transformation

Upon graduation, my Rady MBA has already had a huge impact on my career. Most recently I was promoted to a national position as an innovation advisor for the entire Kaiser Permanente program. Having acquired the business acumen during my Rady MBA, there is no doubt that Rady helped separate me from the crowd and secure this executive role.

Center for Executive Development

Biotech Demystified September 12-14, 2016 This course provides a practical understanding of the basic science powering the biotechnology and pharmaceutical industries. rady.ucsd.edu/exec/open/biotech

Biotech Marketing October 5 & 12, 2016 Unlock commercial potential in the drug development and launch process. rady.ucsd.edu/exec/open/biotech-marketing

Jeff Benabio, MD, MBA ‘15 Physician Director of Healthcare Transformation Kaiser Permanente

I am RadyMade

NEVER STOP ADVANCING

rady.ucsd.edu/radymade

MBA | MFIN | MSBA | Ph.D. | ExecEd


ENHANCING LIFE INNOVATIVE INGREDIENT SOLUTIONS PERFORMANCE FOCUSED | CUSTOMER DRIVEN

Nucelis V I TA M I N D 2

PREMIUM EMOLLIENT FOR THE PERSONAL CARE MARKET

VEGAN SUPPLEMENT FOR THE NUTRITION MARKET

+ 99% PURITY

+ GMO-FREE

+ BIO-BASED

+ NATURALLY SOURCED

+ RELIABLE SUPPLY

+ RELIABLE SUPPLY

www.nucelis.com/products


BIOCOM INSTITUTE

By Liisa Bozinovic, Executive Director, Biocom Institute

People: The Key to Accelerating Life Science Success With people as the life science industry’s most valuable asset, and with enormous unmet medical needs demanding solutions, it is critical to have the right people in the right jobs at the right time. Prepared in partnership with the California Life Science Institute, our 2016 California Life Science Demand Report (The Report) reveals the “state of the union” of California’s talent pool. Companies are working tirelessly to improve the human condition and require the best and the brightest under their roofs. They need well-trained employees so that the life science industry can deliver value more rapidly and efficiently than ever before. From the scrappy start-up with the big idea to the big pharma or medical device manufacturer with a global sales force, people are working across disciplines and navigating national and global landscapes like never before. The Biocom Institute believes that creating an in-depth, biennial study of talent demand reflects our commitment to an ongoing dialogue with California companies, ensuring that talent development is in alignment with industry needs. The 2016 Report, released at the 2016 BIO International Convention, is the leading source of real-time information articulating the specific training, education and skill sets that are most needed by the life science industry. Stakeholders found immediate value in our first report, released in 2014 by a consortium including the Biocom Institute and BayBio Institute. For example, educational institutions have used the data to inform and justify course redesign, new curriculum and industry-responsive programs. With our current supporters, the California State University (CSU) and California Manufacturing Technology Center (CMTC), we have more than doubled the survey data reported since the last time, and universities and schools throughout the state have been eagerly awaiting the release of the 2016 report. Susan Baxter, Executive Director of the CSU’s biotechnology programs explains, “The 2014 Talent Integration Report emphasized the need for strategic alliances between industry associations, universities and companies so we can reduce the gap between what students learn in academia and what skills they’ll need for product development in company settings. This new report provides an updated framework for those ongoing collaborations.” This year’s report includes the following data sets from small, medium and large California-based life science organizations: • 16,000 life science online job postings from Jan-Dec 2015 (in-demand titles and skill sets)

~250 surveys of life science human resource professionals between Jan-Mar 2016 (projected hiring needs by discipline and minimum education level over the next two years, and more) • 35 interviews with life science executives between JanMar 2016 (the current and changing needs with respect to human capital) We are fortunate in California to have the benefit of strong university and community college systems with the ability to develop an abundance of high quality “homegrown talent”. While some executives report they are finding the right talent directly out of the universities, some common themes were noted in the interviews. This year’s data suggests opportunities for fine-tuning the training of our youth for successful careers in life science: • Diversity (race, ethnicity, gender, culture) on teams produces the most robust solutions and best decisions, and greater industry and academic effort is needed to develop this talent pipeline. • Effective communication skills are necessary at all levels, whether it’s the need to communicate across disciplines to bring a drug to market, for sales teams to communicate within the context of a global culture, or engineers and marketing teams to communicate product value. • The shift to value-based health care is creating the need for expanded skill sets in understanding reimbursement and the health care system, structuring business partnerships, relationship management, and policy and regulatory expertise. This statewide study will be a key tool in Biocom and the Biocom Institute’s work with legislators, economic development strategists, academic institutions and other key stakeholders as we work together to bridge industry, academic institutions and workforce training initiatives. Visit our website www.califescienceworkforcetrends.org to download a copy of the report after June 9th.

Liisa Bozinovic is the Executive Director of the Biocom Institute and also heads Biocom’s HR Initiative.

Biocom LifeLines Summer 2016

17


SCIENCE FESTIVAL

By Sara Pagano, Managing Director, Biocom Institute Festival of Science & Engineering

STEM in the Community Inspire, Ignite, Innovate. Three words that could change the path for one child, or an entire classroom. At the Biocom Institute, we understand that in order to accelerate the Southern California life science community, we must create a pipeline of talent and future go-getters. We also acknowledge that in this K-12 space of untapped potential, it is very important to communicate that the foundations of science, technology, engineering and math all play a vital role in learning, which is why we embrace collaboration with many wonderful partners in the STEM space as a whole. Experts agree: “Science has become a tool to teach rather than just a subject. One of the very basic steps in science is to form a hypothesis. ‘What is your best guess, what do you THINK?’ It is clear to me that when we teach kids to THINK, that is when the magic happens. When they know how to THINK rather than just memorize facts; that is when they learn to be innovative and invent, create and build! That is what we all want as parents and mentors, to give them tools to build their future …” Jeane Wong, CEO & founder, The League of Extraordinary Scientists & Engineers. Our Inspire, Ignite, Innovate program brings industry professionals into the classroom and engages students in an informal learning environment where curiosity leads to future passion. Children are already born with an inquisitive nature to learn, but it’s everyone’s job, not just teachers, to spark that sustained level of excitement for science, technology, engineering and math, and inspire the minds of young people. If you think about moments in your education that led you to your current occupation, oftentimes it connects back to an experience. Perhaps it was a special project that made you think differently about how the earth rotates, a field trip that prompted you to ask for a stethoscope for your birthday, or a guest speaker who made you wonder “what if”? The Inspire, Ignite, Innovate program helps to create these experiences through sharing stories, teaching a lesson, participating in an experiment, or simply being present in a classroom to engage in dynamic conversations where students can engage in learning beyond textbook reading. During the 2016 San Diego Festival of Science & Engineering, in collaboration with our industry partners, we brought Biocom Career Days to four of the STEAM Magnet Elementary Schools in San Diego. Through an interactive panel, we were able to communicate the importance of STEM to elementary school students, and this time we added the “A”, for the Arts, that is. STEAM education is giving educators, students and families space to explore the connections between art and design with science, technology, engineering and math. Students are making connections across subjects, working collaboratively to solve real world challenges, and

18

Biocom LifeLines Summer 2016

sharing their solutions in creative ways. “Today’s connected world is requiring us to think globally, creatively and across sectors…” says Kim Richards, founder of STEAM Insight. Each panelist represented a different “STEAM” letter based on their role within the industry and throughout their discussion, they communicated to the students the connections their letters, or industries rather, had to one another. At the close of our first career panel, three students, with eagerness in their eyes, jumped up and dashed towards the stage. With pens in hand, they proceeded to ask each of our panelists for their autographs, and just as suddenly, our hearts melted because we knew we had just created one of those experiences that would soon make a huge impact on the future education of those three students. If you INSPIRE a student, it will IGNITE an interest to INNOVATE. Help us create the next generation of innovators! For more information and to participate, visit us at www.lovestemsd.org

Sara Pagano is the Managing Director of the San Diego Festival of Science & Engineering

The San Diego Festival of Science & Engineering, Presented by Illumina, proudly thanks our 2016 sponsors for making this year’s festival a success: GOLD Level: ABC 10 & Azteca America, CBS Radio, Qualcomm, Think Blue - City of San Diego, ViaSat, Inc. SILVER Level: Cox Communications, Hologic, Inc., Reuben H. Fleet Science Center, San Diego County Office of Education, San Diego Padres, Scatena Daniels Communications COPPER Level: Anthem Blue Cross Foundation, Cubic Corporation, Cymer, Ferring Pharmaceuticals, Geek Girl, Genentech, Livewell San Diego, Sprout by HP, Thermo Fisher Scientific, Univision, UTC Aerospace Systems – Aerostructures, Vertex, VWR KRYPTON Level: Ardea Biosciences, BP America, C2 Education, Johnson & Johnson Jlabs, Microsoft, MilliporeSigma, Mission Federal Credit Union, Northrop Grumman, Pfizer, Inc., San Diego County Credit Union, Westpack, Inc TITANIUM Level: Ascent Street Boards, Conatus Pharmaceuticlas, General Atomics, International Bridge Technologies, Inc., Kaiser Permanente, Leidos, Nanoimaging Services, Nordson,Point Loma Nazarene University, Puro Sound Labs, Quidel, Raytheon, San Diego Foundation, San Diego National Defense Industrial Association, UCSD Extension We Love STEM Level: American Elements, D&K Engineering, Lakeshore Learning, Promo Shop, Inc., San Diego County Fair, San Diego Financial Literacy Center, Vertex, UTC Aerospace Systems – Aerostructures STEM Champions Level: Alma Life Sciences, Canale Communications, Chempetitive, Padres Foundation, WD-40 Foundation and Workforce Partnership. Thank you San Diego!


MEMBERS IN ACTION BIOCOM INSTITUTE FESTIVAL OF SCIENCE & ENGINEERING SAN DIEGO:

The Biocom Institute Festival of Science & Engineering’s eighth annual Expo Day took over Petco Park, featuring more than 130 different interactive exhibits and 15 exciting stage performances highlighting all things STEM. Over 24,000 San Diegans attended the Expo at Petco Park, which kicked off Festival Week this year.  Mayor Faulconer made a stop at STEM In Your Backyard: City Heights to chat with future scientists, Illumina taught students about DNA sequencing, while Qualcomm’s interactive robots roamed all over the park. 

Biocom LifeLines Summer 2016

19


MEMBERS IN ACTION A BUSY START TO 2016:

March found our Biocom Institute in full swing with their Hack-a-Thon for Health (with students demonstrating their social data science skills) and the wellattended Brushes to Beakers night for the 21+ crowd. Recently, Pfizer welcomed the Institute’s ILSE participants to their campus. The Introductory Life Sciences Experience provides a re-entry path into a STEM career in life sciences for Out-of-School Youth ages 17-24. Meanwhile, there was great interest in a workshop on California tax credits and grants available to life science companies. Finally, large crowds could be found at Biocom’s CEO Reception, where they met our new Executive Director of our Los Angeles office, and at the annual San Diego Economic Development Corporation Dinner.

20

Biocom LifeLines Summer 2016


MEMBERS IN ACTION A HOLE IN ONE: The Biocom Charity Golf

Tournament hosted 136 life science professionals at the Santaluz Club for a day of fellowship on the greens, camaraderie, and networking on a perfect San Diego day. All proceeds went to support Biocom Institute’s workforce development initiatives, transitioning veterans programs and STEM education in Southern California.

22

Biocom LifeLines Summer 2016


MEMBERSHIP

By Kira Jenkins, Sr. Director of Membership, Biocom

To Listen Means to Know As the Greek philosopher Epictetus said, “We have two ears and one mouth so that we can listen twice as much as we speak.” At Biocom, we take pride in being an organization that actively listens to its members. We seek and value ongoing member input, recognizing that it yields a collective voice driving our course. Annually, we look at the needs, direction and input of our diverse membership as we set our organizational goals. As a memberdriven organization, we pivot to the discrete needs of our members, creating opportunities and programs for the smallest startup to the largest multinational, and deliver them in a customized fashion across all of the life science clusters we serve. Our aim is to show value year over year to organizations that continue their membership. Reflecting that value, we have 17 members that have been with us since our founding, more than 20 years ago. Through the years, we have developed new specialized committees, launched timely initiatives, created customized events and brought in knowledgeable speakers at the request of our membership. Like any good business, we constantly reevaluate, discontinuing programs or events that no longer serve our members. Here are some examples of member-driven initiatives and programs resulting from our ongoing listening campaign. CRO Initiative The Biocom CRO Initiative began in 2010 with a handful of CRO members talking to Biocom staffers about how they would like to increase their visibility and grow their footprint in San Diego. The consensus was that with a collective voice, they could successfully achieve this goal. Today, Biocom has more than 100 CRO members. We actively exhibit as the Biocom CRO Group at various international trade shows. We help the group develop programming for member companies as well as share best practices. We have also built a web site to easily connect members to the appropriate CRO for their needs based on their stage of development. More information can be found at www.biocomcro.org. Biocom Concierge We recognize that every company requires help on the path to success and that finding dependable service providers can be time-consuming and difficult. Two years ago we launched www.biocomconcierge.com, a searchable database that connects a member’s needs with the services of a fellow Biocom member. HR Events Biocom launched the California Life Science HR Conference seven years ago in response to a meeting from a handful of members interested in pulling HR Executives together. They wanted to openly share best practices, learn from one another and continue to build their own networks with like-minded individuals who shared similar challenges. Now in its 7th year this conference

24

Biocom LifeLines Summer 2016

is a must-attend for all senior level HR Professionals. This year’s event entitled: Where is the Workforce Headed from a Biotech Perspective will take place on October 19-20, 2016 in San Diego at the Alexandria. Partnering Events Sometimes it begins with people in a room sharing ideas. Biocom’s Global Partnering Conference was started by four extremely committed individuals who are still active in the planning of an always well-attended conference, six years later. Jennifer Cayer, Jim Schaeffer, Igor Bilinksy and Mark Wiggins would often talk about how they would run into each other making the rounds at various partnering conferences, but hardly ever saw one another in San Diego. By reaching out to their own networks, they succeeded in attracting the heads of Licensing and Business Development from major pharmas and biotech companies from around the globe, interested in attending an intimate, two-day event focused on deal-making. This event has become one of the best partnering conferences for high level access to decision makers for our industry. More information can be found at www.biocomglobalpartnering.com. Specialized Committees All of Biocom’s 16 committees actively drive programming while providing members with the opportunity for networking, exchanging best practices, and discussing issues of common interest. Most recently, Biocom launched the Regulatory Affairs Committee to address regulatory and scientific issues faced by California’s life science community, at home and abroad. Committee members are at the forefront of FDA’s and other agencies’ activities through regular legislative and regulatory updates and have the opportunity to review and recommend positions on new proposals and guidance. Two Ears, One Mouth We listen and then we speak. That is true at home as well as abroad. From an International perspective, we are continuously working with global centers of innovation to identify partners to assist members with their worldwide growth. Our staff in Tokyo listens to our members and provides a gateway to Asia. Our deep relationships with life science organizations across Europe open avenues for critical networking. Biocom’s staff of 30 professionals is dedicated to the individual needs of our members and on Accelerating Life Science Success.

Kira Jenkins is the Director of Membership for Biocom and also formed and spearheads Biocom’s Digital Health and CRO committees.


LLC

P h a r m aceu t ical D evelo p m en t , Man u f acturing and R e g u l a t o r y So lu t io n s — f ro m P reclin ical t o Commercial

A Custom Approac h t o D r u g D e v e l o p me n t

IriSys provide s individualiz e d se rvic e s f or U.S . a nd intern at ional c om panie s re lat e d t o t he FD A phar m a c e ut ic a l ap proval proc e ss inc luding analyt ic al and f or m ula t ion develo p ment , c G M P m anuf ac t uring and re gulat ory s t r a t e g ie s . Analytical Methods | Formulations & Processes Specialized Technologies | All Dosage Forms Pre-IND Packages | CMC & IND Filings cGMP Clinical Supply | Commercial Manufacturing www.irisys.com | contact@irisys.com 858.623.1520 San Diego, CA


Boehringer Ingelheim BioXcellence™

Producing value – Boehringer Ingelheim BioXcellence™, your trusted partner Boehringer Ingelheim Contract Manufacturing has now evolved into Boehringer Ingelheim BioXcellence™ – your dedicated biopharma contract manufacturer. Boehringer Ingelheim BioXcellence™ is a leading biopharmaceutical contract manufacturer with more than 35 years of experience – and more than 25 biopharma products brought to market. We promise clear advantages for our customers by providing: • Transparent modular approaches geared to provide flexibility • Tailor-made solutions – where you need us, when you need us • Secured supply of material throughout the entire product lifecycle • Seamless integration with every step of your business process

In order to discuss your specific needs in detail please contact us – we will make your product our passion! Contact us: www.bioxcellence.com


PURCHASING GROUP

By Rick Fultz, Managing Director, Biocom Purchasing Group

Accelerating Growth & Changing the Game Proprietary RFP Process

5,000,000+ data points reviewed in the bid process

20

supplier & manufacturer meetings

35k pages of RFP responses and member information

100 hours of committee meetings

58 committee members, advisors, PG board members + PG staff

Innovation can take many forms. Over the course of the past eighteen months, scientists, lab managers, procurement and supply chain specialists, financial advisors and executive leaders across the Biocom membership have united together with one common goal: leverage significant current and future spend to create a group Lab Supply contract that is more advantageous for our members than any other contract of its kind in the world. Our stakeholders have a shared interest in modeling Biocom and our contracts for 21st century innovation. With our new 2020 Strategic Plan, we have a renewed focus, and the bandwidth necessary, for the future-facing business needs in the Southern California region. While we have come a long way in our 20 years as an organization, it is apparent now more than ever that we are seen as an integral resource in the race to drug discovery, securing capital funding and retaining top talent in the workforce. Sometimes, quantity has a quality all its own. In an industry historically identified as keeping pipeline projects and organizational operations close to the vest, Biocom member companies defied stereotypical tendencies for secrecy in their latest quest for securing an industry-leading Lab Supply contract. While all members signed detailed confidentiality agreements, privacy regarding procurement practices between committee members took a back seat in the shared goal of fortifying a contract that would best suit the wide array of Biocom member company needs. This was by far Biocom Purchasing Group’s deepest dive into an open market for an RFP to date. With over 5,000,000 data points, 35,000 pages of information, 200 supplier and manufacturer meetings, 90 hours of committee meetings, and endless (and sleepless) days of legal review and staff time, we are very confident that we left no stone unturned. The committee members engaged with industry executives, procurement professionals and technology specialists to brainstorm new ways

to move from ideating to innovating and have structured this new lab supply contract accordingly. They pressed on both finalists to experiment with different cost structures, trying to capture the majority spend of Biocom companies all the while planning and accounting for future growth. The committee asked for the moon and both finalists delivered. Changing the Game The lab supply environment in Southern California and around the world is rapidly changing, and our RFP committee made it their mission to form a contract focused on articulating the value of regional success while leveraging global resources. The new contract gained from this process supports the gamut of companies ranging from start up to big pharma by removing business, financial and operational obstacles. This allows Southern California entrepreneurs to enjoy access to core research solutions through deep discounts, operational capabilities, educational programs and Biocom memberships’ myriad of expertise. We were told an RFP of this magnitude could not be done. Those same doubters conceded that if we could, it would change the industry. Our members are now armed with a market changing contract that provides exclusive benefits, price points, terms and conditions that rival (and in some case beat) those of even the biggest Pharma companies. We are confident their access to the industry changing contract will positively affect their ability to discover and produce lifesaving therapies to make our world a better place, which made this whole process very much worth the effort. For more details on the process, the winner, and how to take advantage of this incredible benefit visit www.biocom.org/wechangedthegame. Rick Fultz oversees membership and sponsorship efforts, business development opportunities, and the Biocom Purchasing Group.

Biocom LifeLines Summer 2016

27


BIOCOM IN THE NEWS

Biocom’s Making Headlines If you didn’t already know that it’s been a busy few months for Biocom, the quantity and diversity of these headlines tell the story. Here’s a quick scan of the articles that have recently appeared in some of the top local and state-wide publications as Biocom’s leaders get the word out about drug innovation, workforce development, geographic expansion and other key issues that matter to our members. Read the brief excerpts here:

April 27, 2016 Business: San Diego’s Biocom opens LA Office Areas look for mutual benefit as San Diego exports biotech expertise to its big brother By Bradley Fikes Hoping to bring the region’s life science savvy to Los Angeles, the San Diego-based trade group Biocom has opened an office in the downtown heart of its northern neighbor. The new site provides a closer nexus for Biocom’s efforts to help the Los Angeles area organize its talent-rich but sprawling biomedical industry, said Joe Panetta, the group’s president and chief executive. Biocom’s latest office stems from a report commissioned by the Los Angeles County Board of Supervisors to outline what’s needed to develop a successful biotech cluster in the area, Panetta said. “We decided to take the leap and open an office and hire an executive director because we think there’s an enormous opportunity to bring together the life-science community down here in San Diego and the life science community up in L.A.” Read more at: http://bit.ly/1VUVstT

February 28, 2016 Op-Ed: Breakthrough drugs cost a lot to develop and save lives By Joe Panetta As politicians and pundits continue to decry the high cost of prescription drugs, one important fact is missing: Breakthrough biopharmaceuticals improve millions of peoples’ lives every year and reduce costs for the health care system as a whole. The novel drugs that ultimately reach patients do so because of an enormous amount of risk taken on by investors and entrepreneurs – and the dedicated efforts of a life sciences workforce that exceeds 200,000 statewide. The biopharmaceutical industry encourages a more thoughtful consideration of the efforts involved in bringing life-changing drugs to market, where they improve patients’ lives in remarkable, priceless ways. Read more at: http://bit.ly/1ZFN1jP

May 10, 2016 Biotech trade group Biocom expands to L.A. By James Rufus Koren A San Diego trade group seeking to boost the Southern California biotech industry is now setting up shop in downtown Los Angeles, a northward shift that could step on the toes of L.A.’s own homegrown biotech association. “It’s an opportunity to bring together the life-science entities in Los Angeles and bring that group together with the community in San Diego,” Joe Panetta said. Biocom has already been active in Los Angeles. It’s one of a handful of groups working with the Los Angeles County Economic Development Corp. on a plan to build up L.A. County’s biotech industry by attracting companies to the region and helping them expand. Read more at: http://lat.ms/1sdWSmY

Continued Pg 30

28

Biocom LifeLines Summer 2016


Percent of total GeneTests genes covered

Reveal Greater Coverage Depth in WES 60.0

Roche MedExome

Supplier A's Clinical Research Exome

50.0 40.0 30.0 20.0 10.0 0.0 <90% 90-97% 97-100% 100% Percent of each GeneTests gene’s coding bases covered at ≥20X

Figure 1. With SeqCap EZ MedExome, 53% of medically relevant genes are covered at 100% (≥20X coverage) vs. 6% by Supplier A’s Clinical Research Exome. Percentage of bases covered at ≥20X for each consolidated target was determined using GATK (DepthOfCoverage), summarized by gene. Supplier A kit’s data was generated by a third-party sequencing service provider, following Supplier A’s protocol. All reads were subsampled to 60 million for assessment, then subjected to the same bioinformatics pipeline for analysis. Roche data on file.

For life science research only. Not for use in diagnostic procedures. NIMBLEGEN and SEQCAP are trademarks of Roche. © 2015 Roche 581-61699-0915

Achieve greater coverage depth from less sequencing through the enhanced coverage of the new SeqCap EZ MedExome Target Enrichment Kit for whole exome sequencing (WES). Rely on a design developed to enrich the entire exome, but particularly optimized for analyzing genes of medical relevance (Figure 1) in research studies. • Focus on genomic regions that really matter For disease-associated genes, 98% of bases are covered at ≥20X depth. • Call variants with confidence Detect SNPs with 98% sensitivity and >99% specificity for SNP allele classification. • Gain greater efficiency at minimal cost Reduce sequencing cost through uniform coverage and fully supported multiplexing protocols.

Reveal more about the exome Learn more about how the SeqCap EZ MedExome Target Enrichment Kit can improve your whole exome sequencing by visiting sequencing.roche.com/medexome.html or calling 800-262-4911.

Roche Diagnostics Corporation 9115 Hague Road Indianapolis, Indiana 46256


BIOCOM IN THE NEWS

Scrip

Pharma intelligence |

May 4, 2016 Opinion: A Vision for Boosting the Life Sciences in San Diego and Beyond By Joe Panetta The life sciences industry represents a vital piece of San Diego’s innovation economy, contributing $31.8 billion each year in local economic impact—more than defense or even tourism… The Biocom leadership team, along with more than 100 senior executives in our community, recently completed a 2020 strategic plan that answers the important question: How do we, as a business community, ensure that San Diego maintains and expands its leadership as a life science hub? We identified a range of specific initiatives to help our life sciences companies expand regionally and compete better globally—taking into account things like emerging technology, the changing workforce, and the always-transforming healthcare market. Now Biocom is working with the City of San Diego and other stakeholders to achieve these goals by 2020. Read more at: http://bit.ly/1ZfFwzZ

February 26, 2016 Soon-Shiong Envisions Better, Ultimately Cheaper Cancer Care By Mandy Jackson Describing biotech billionaire Patrick Soon-Shiong as a big thinker is an understatement given the goals that he and his web of businesses have for improving the way cancer patients are treated, and now he’s enlisting the help of other biopharma companies to test immunotherapy hypotheses. In fact, to find the best treatments for all the myriad types of cancer, it’s essential that as many researchers and drug developers as possible get involved in the Cancer MoonShot 2020 initiative led by Soon-Shiong and other companies, to bring their therapeutic vaccines, immuno-oncology drugs and targeted therapies to the table. That’s why Soon-Shiong has been on a roadshow recently to talk to oncologists, scientists and biopharma executives, including a stop on Feb. 25 at Biocom’s Global Life Science Partnering Conference in San Diego. Read more at: http://bit.ly/24LXo9o (Subscription required.)

A National Leader in High-Performance Computing & Big Data Partnering with local biotech companies to accelerate discovery

Biotechnology innovation in areas such as genomics, microbiomics, pharmaceuticals, and precision medicine is increasingly driven by informatics, requiring large scale computation and storage. SDSC’s array of computational infrastructure and storage, along with its cadre of experienced scientists and engineers, is leveraged by local companies to provide support in next-generation sequencing analyses, drug discovery, translational medicine, and other areas. We provide: h h h h h h

Collaborative Research Opportunities HPC and Storage System Architecture and Design Big Data Expertise and Training Machine Learning and Predictive Analytics Bioinformatics Programming and Applications Data Science Training

Join us Sept. 29th for a breakfast workshop: SDSC’s Big Data Resources for Biotech Research Email or visit us online to see how we can help you reach your research objectives. www.sdsc.edu/collaborate/ipp.html | ipp@sdsc.edu


PREMIUM MEMBERS AbbVie Airgas Aldevron Alexandria Real Estate Equities Althea Bayer Barney & Barney Biogen Biomed Realty Trust Biospace BP Biosciences Center Bridge Bank California Manufacturing Technology Consulting Canale Communications Celgene COI Pharmaceuticals

Conatus Pharmaceuticals Cooley LLP Deloitte DLA Piper Dowling & Yahnke Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific GE Healthcare Life Sciences Genoptix Hologic Illumina J-Labs Jones Day KPBS KPMG

Latham & Watkins Mentus Merck Research Laboratories Mesa Biotech* Mintz, Levin, Cohn, Ferris, Glovsky and Popeo Novo Nordisk NuVasive Office Depot Pfizer Prometheus Laboratories PwC Thermo Fisher Scientific Unisource Solutions VWR International Wilson Sonsini Goodrich & Rosati * New Members from March 2016 to May 2016

BIOCOM STRONG At Biocom, we are strong because of our members. Each of Biocom’s member companies and organizations contribute in a unique, impactful way to the innovation that makes this region such a powerful force in the global life science industry. Every day, you are working to save lives and make a difference. Together we are all Biocom Strong. Here is one example of a testament provided to us by our member Tioga Research: Relieving the Pain of Osteoarthritis Osteoarthritis, a progressive deterioration of joints, can be a painful and debilitating condition that affects an average of 7.7M patients in the US each year. In the year 2005, it was estimated that 26.9M US adults were affected, and over 3 million hospitalizations in 2011 had osteoarthritis as the principle diagnosis. The San Diego based Tioga Research team (originally launched as fqubed, and, following acquisition, then operating as the research division of Toronto-based Nuvo Research) was challenged to develop a diclofenac formulation that would be suitable for topical application, namely to the skin surrounding the knee joint (diclofenac is a non steroidal anti-inflammatory drug (“NSAID”) – the class of drugs that includes ibuprofen, ketoprofen and celebrex). While the oral form of diclofenac is effective, ingesting any NSAID orally increases the risk of internal bleeding; an estimated 18,000 people in the US die each year from this complication. The Tioga Research team, then at Nuvo, succeeded in devising a product that could be topically applied and achieve an effective localized dose of diclofenac in the joint, with minimal side effects. Devising patentable formulations for topical or transdermal administration is a strength of the Tioga Research team, and the product was an early example of this special strength. The patent claiming these novel formulations as compositions of matter issued in 2012; the product was approved by the FDA in February 2014 and is now being prescribed to thousands of U.S. patients each year (US sales of the product in the first quarter of 2016 were $55M).

If you are a Biocom member and would like to be featured in our Biocom Strong campaign please email Kira Jenkins at Kjenkins@biocom.org.

32

Biocom LifeLines Summer 2016


PREMIUM MEMBER SPOTLIGHTS www.altheacmo.com

www.cooley.com Name: Wainwright Fishburn, Jr. Job title: Partner

Name: Erica Raether Job title: VP, Human Resources

Favorite movie: Pulp Fiction Favorite books: The Patient Will See You Now by Dr. Eric Topol Favorite quote: “Everything is hard until it gets easy.” --Duane Roth, Former CEO, CONNECT Favorite restaurant or meal: Mexican food, third generation Arizonian Favorite city: Paris, France Favorite thing to do on the weekends: Distance cycling What CD can we find in your car: Bruce Springsteen Favorite hobby: Wine and antique cars Favorite website: Nature.com Favorite spot in Southern California: On the sand at La Jolla Shores First job: Restaurant runner serving Frank Sinatra If you could have another career, what would it be: I wouldn’t do it any differently. Why did you start working in your industry: I was not a scientist of an engineer, but I love helping creative people bring their ideas to fruition.

Favorite movie: Swingers Favorite books: The Alchemist Favorite quote: “It’s better to be kind than right” Favorite TV show: Freaks and Geeks Favorite restaurant or meal: Thai Favorite city: London, England Favorite thing to do on the weekends: Spending time with my family and checking out local craft fairs and farmers markets What CD can we find in your car: Tame Impala Favorite hobby: My awesome daughter and husband Favorite website: Flipboard and Etsy Favorite spot in Southern California: Ojai First job: Video store clerk Favorite part of your job: Fostering Althea’s culture and creating an environment where employees feel valued and want to do their best work If you could have another career, what would it be: Personal Coach Why did you start working in your industry: I’ve always had a passion for helping others. Althea provides me the opportunity to be a part of seeing patients from around the world benefit from our employees’ efforts.

www.business.officedepot.com Name: Donna Kimball Job title: Major Account Manager Favorite movie: The Godfather, The Way We Were Favorite books: Eat, Pray, Love....I prefer to read magazines Favorite quote: “I’ve learned that people will forget what you said, people will forget what you did, but people will never forget the way you made them feel.” Maya Angelou Favorite TV show: Grey’s Anatomy, Nashville, Scandal Favorite restaurant or meal: Italian

Favorite spot in Southern California: Coronado and Del Mar First job: Shorty Mack’s Ice Cream Shop..serving ice cream and making sandwiches Favorite part of your job: Relationships made with my​customers and co-workers​ If you could have another career, what would it be: Acting, musical theater or gemologist Why did you start working in your industry: I worked with an office supply company back in Penna. after college at the same time I was teaching in an elementary school.​I moved to San Diego from Penna. and found a job in the office products​industry. I found sales in this industry​ to be rewarding and a great way to meet people and develop relationships. I actually met my husband while cold calling his company. The rest is history as they say.

Favorite city: Florence or London Favorite actor/actress: Meryl Streep Favorite thing to do on the weekends: Sporting events​, e​ ating out with my husband, shopping What CD can we find in your car: Chicago, Earth Wind and Fire, Crosby, Stills, Nash and Young... and yes I still have CD’s in my car along with my iphone playlists.​ Favorite hobby: Walking, musical theatre, movies, writing poetry Favorite website: Facebook, Google

Biocom LifeLines Summer 2016

33


BOARD OF DIRECTORS BOARD OFFICERS AND EXECUTIVE COMMITTEE: CHAIR: Theodore Schroeder, Zavante Therapeutics* VICE CHAIR: Carin Canale-Theakston, Canale Communications* CHAIR ELECT: Daniel Burgess* VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, J.D., Ph.D., DLA Piper* VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young* VICE PRESIDENT – INDUSTRY: Christophe Schilling, Ph.D., Genomatica, Inc.* VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield* CHAIR EMERITUS: Magda Marquet, Ph.D., Althea* PRESIDENT & CEO: Joe Panetta, Biocom* Vincent Anido, Ph.D., Aerie Pharmaceuticals Steven Bartz, Ph.D., Merck & Company Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo Michael Brown, Stradling Yocca Carlson & Rauth Sandra Brown, Ph.D., UCSD Terrance J. Bruggeman, Avenzoar Pharmaceuticals, Inc. Bruno Buisson, Ph.D., Neuroservice Carol Cox, NuVasive Charles Dadswell, Illumina* John M. Dunn, Vital Therapies David Enloe, Althea CMO Stephen Ferruolo, J.D., Ph.D., USD School of Law* Oliver Fetzer, Ph.D., Synthetic Genomics M. Wainwright Fishburn, Jr., Cooley LLP* Don Fitzgerald, Genentech Jack Florio Gregory Fond, Sanofi Global R&D Gregory Frost, F1 Oncology Carol Gallagher Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Richard Heyman, Ph.D., Metacrine Guy J. Iannuzzi, Mentus Gerald Joyce, M.D., Ph.D., Genomics Institute of the Novartis Research Foundation David Kabakoff, Ph.D., Sofinnova Ventures Katherine Kantardjieff, Ph.D., California State University San Marcos Paul Laikind, Ph.D., ViaCyte Jacob Levin, Ph.D., UC Irvine James Levine, Sapphire Energy* Jack Lief, BioRegenerative Sciences, Inc.* James Mackay, Ph.D, Ardea Biosciences

Damien McDevitt, Ph.D., GlaxoSmithKline Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.* Tracy Murphy, Biomed Realty Trust* Perry Nisen, M.D., Ph.D., Sanford-Burnham Prebys Medical Discovery Institute Steven Pacelli, Dexcom Richard Pascoe, Apricus Biosciences* Kenneth Polin, Jones Day Trindl Reeves, Barney & Barney LLC* Dan Ryan, Alexandria Real Estate Equities Camille Saltman, Malama Composites, Inc. Dean Samsvick, KPMG James Schaeffer, Ph.D., Calibr* Timothy Scott, Pharmatek* Bhasker Shetty, Ph.D., Pfizer La Jolla Larry Stambaugh, Kalos Therapeutics* Mark Stevenson, Thermo Fisher Scientific* Tsuneo Takahashi, NF Corporation Kenneth Weixel, Deloitte & Touche, LLP Stephen Welter, San Diego State University Tom West, Hologic Matthew Williams, AbbVie Scott N. Wolfe, Latham & Watkins LIFE DIRECTOR: Kennon W. Baldwin, Ferguson Pape Baldwin Architects* David Hale, Hale BioPharma Ventures* Brent D. Jacobs, Cushman & Wakefield* Magda Marquet, Ph.D., Althea* Tina Nova, Ph.D., Molecular Stethoscope Biocom Board Members-Ex-Officio: Mark Cafferty, San Diego Regional Economic Development Corporation Peter Callstrom, San Diego Workforce Partnership Sunita Cooke, Ph.D., Mira Costa College Scott Lippman, MD, Moores Cancer Center, UCSD Greg McKee, CONNECT Peter Preuss Jerry Sanders, San Diego Regional Chamber of Commerce David Webb, Ph.D., Scripps Research Institute *Executive Committee Member

COMMITTEE LEADERSHIP Big Data Larry Smarr, Cal(IT)2 Biocom Institute Board Committee* Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc. Capital Development Committee* Carin Canale-Theakston, Canale Communications David Kabakoff, Ph.D., Sofinnova Ventures CRO Committee Timothy Scott, Pharmatek Environmental, Health and Safety Committee Cliff Hanna Dan Shiel, Pfizer La Jolla

34

Biocom LifeLines Summer 2016

Facilities Committee Andy Darragh, Ferguson Pape Baldwin Architects Brent D. Jacobs, Cushman & Wakefield

Medical Device Committee Mike Oliver, Spectra Science Joleen Schultz, Rady School of Management, UCSD

FDA Committee David Enloe, Althea CMO Michele Yelmene

Digital Health Committee Apurv Kamath, Dexcom

Intellectual Property and Patent Law Committee Daniel Hart, Knobbe Martens Olson & Bear LLP Michael Mueller, Conatus Pharmaceuticals International Committee Kenneth Polin, Jones Day Legislative Committee Richard Ledford April Grant, Sunovion Pharmaceuticals

Public Policy Oversight Committee* Larry Stambaugh, Kalos Therapeutics Paul Laikind, ViaCyte Purchasing Board Committee* Jack Lief, BioRegenerative Sciences, Inc. Veterans Committee Josh Vosovic, Accenture Accelerated RD *Board Level Committees


BIOCOM MEMBERSHIP PREMIUM

AbbVie Airgas Aldevron Alexandria Real Estate Equities Althea Bayer Barney & Barney Biogen Biomed Realty Trust Biospace BP Biosciences Center Bridge Bank California Manufacturing Technology Consulting Canale Communications Celgene COI Pharmaceuticals Conatus Pharmaceuticals Cooley LLP Deloitte DLA Piper Dowling & Yahnke Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific GE Healthcare Life Sciences Genoptix Hologic Illumina J-Labs Jones Day KPBS KPMG Latham & Watkins Mentus Merck Research Laboratories Mesa Biotech* Mintz, Levin, Cohn, Ferris, Glovsky and Popeo Novo Nordisk NuVasive Office Depot Pfizer Prometheus Laboratories PwC Thermo Fisher Scientific Unisource Solutions VWR International Wilson Sonsini Goodrich & Rosati

BIOTECH

3-V Biosciences Abbott Laboratories Abgent Abide Therapeutics Abwiz Bio ACADIA Pharmaceuticals ActivX Biosciences Advanced BioMatrix Advanced Targeting Systems Aerie Pharmaceuticals Agena Bioscience Aimmune Therapeutics Allakos AM Chemicals Ambryx Biotechnology

Amgen Amicrobe AmpliPhi Biosciences Amplyx Pharmaceuticals Amyris Amgiocrine Bioscience* Animantis* AnaptysBio Animal Cell Therapies Ansun Biopharma Apricus Biosciences Aptose Biosciences Aratome Arcturus Therapeutics Arcus Bioscience Ardea Biosciences Arena Pharmaceuticals Armetheon Arrayomics Arytha Biosciences Asahi Kasei Pharma Astellas Pharma aTyr Pharma Avantgen Avelas Avenzoar Pharmaceuticals* Avidity NanoMedicines Aviva Biosciences Bachem Americas BASF Beloteca BioLegend Biomatrica Biomyx BioNano Genomics Bionomics BioRegenerative Sciences* Bird Rock Bio Biosortia Pharmaceuticals BioSpyder Technologies BioWa Boehringer-Ingelheim BP Biosciences Center CalAsia Pharmaceuticals* CalciMedica CannaVest Corporation Cell Applications Cellics Therapeutics Center for Aquaculture Technologies Channel Medsystems Chubu Technology Licensing Office Cibus Cidara Therapeutics Circuit Therapeutics Coda Therapeutics Coherus Biosciences Conju-Probe Contract Biotics Crinetics Pharmaceuticals Curtana Pharmaceuticals Cyprus Therapeutics CytomX Therapeutics Dart Neuroscience Definiens Dermata Therapeutics Diomics Corporation DNA Link USA DNAtrix DSM Food Specialties

EA Pharma Co., Ltd E&B Technologies Edico Genome eFFECTOR Therapeutics Elcelyx Therapeutics Electronic BioSciences Emerald Therapeutics eMolecules Epeius Biotechnologies Epitracker Eton Bioscience Evofem Fabrus Fate Therapeutics FibroGen* Forge Therapeutics Forty Seven Galena Biopharma Genelux Corporation Genentech Genlantis Genoa Pharmaceuticals Genomatica Genovo Corporation GenSignia Life Sciences GigaGen GlaxoSmithKline Global Medical & Research Technologies GWR Instruments Halozyme Therapeutics Helix Heron Therapeutics Histogen Horizon Pharma USA Human Longevity Huya Bioscience International IDEXX BioResearch Imprimis Pharmaceuticals Inception Sciences Indi Molecular Inhibrx InnoPep Innovative Cell Technologies Innovus Pharmaceuticals Inovio Pharmaceuticals InSilixia Integrated DNA Technologies Intercept Pharmaceuticals International Stem Cell Intrexon Corporation Intrinsic LifeSciences Invetech InvivoGen Ionis Pharmaceuticals IRBCo. JSR Micro Kalos Therapeutics Kalyra Pharmaceuticals Kindred Biosciences Koltan Pharmaceuticals Kura Oncology Kyowa Hakko Kirin California La Jolla Biologics La Jolla Pharmaceutical Company Ligand Pharmaceuticals Laguna Pharmaceuticals Leading Biosciences Linkage Bioscience

Lion Biotechnologies Lpath Lumena Pharmaceuticals MabVax Therapeutics Malama Composites MAPP Pharmaceuticals Mast Therapeutics MDRejuvena MEI Pharma Meiji Seika Pharma Metacrine Mirati Therapeutics Molecular Response Molecular Stethoscope Monsanto MultiVir Myokardia Nagano Science USA Nautilus Environmental Neothetics NeuroGenetic Pharmaceuticals NF Techno Commerce Nitto Denko Technical Novartis Pharmaceuticals Novoron Bioscience Novvi Nucelis Nurix OBI Pharma USA Ocera Therapeutics Ohr Pharmaceutical Omniox Optimum Therapeutics Orexigen Therapeutics OrPro Therapeutics Otonomy Oxford Bio Therapeutics Pacira Pharmaceuticals Panmira Pharmaceuticals Patara Pharma Pathway Genomics PersImmune Pfenex PharmAkea Pliant Therapeutics Polaris Group Polynoma PolyPeptide Group Poseida Therapeutics Predictive Biology PrimeGen Biotech Primordial Genetics Principia Biopharma Prognosys Biosciences ProSci QED Bioscience Receptos Services Regulus Therapeutics REKA Health Rempex Pharmaceuticals Renova Therapeutics Repertoire Genesis Retro Virox REVOLUTION Medicines Ribomed Biotechnologies Ridgeline Engineering RIFT Biotherapeutics Roche Applied Science Rohto Pharmaceutical

Roswell Biotech RQX Pharmaceuticals Salveo Dx* Sapphire Energy Samumed Samsara Sciences Sanofi Scilex Pharmaceuticals Scripps Laboratories Second Genome Senior Scientific Senomyx SentĂŠ Sentynl Therapeutic Seragon Pharmaceuticals SGB Silicon Biosystems Solstice Biologics SomaLogic Sophiris Bio Sorrento Therapeutics SOVA Pharmaceuticals Sparsha Pharma USA StemCells Stemedica Cell Technologies StemImmune StemoniX StemProtein Sunesis Pharmaceuticals Sunovion Pharmaceuticals Sutro Biopharma Synthetic Genomics Takeda Pharmaceuticals U.S.A. Tanabe Research Laboratories Tarere Therapeutics Target Discovery TEGA Therapeutics Tenova Pharmaceuticals Theravance Thesan Pharmaceuticals Tocagen Tonbo Biosciences TP Therapeutics Tracon Pharmaceuticals Tragara Pharmaceuticals Triphase Accelerator Triton Health & Nutrition UCB US Specialty Labs Vantari Genetics Vaxiion Therapeutics Verdezyne Vertex Pharmaceuticals Vet-Stem ViaCyte Vical Viking Therapeutics Visionary Pharmaceuticals Vital Therapies Wellspring Biosciences Wildcat Discovery Technologies World Fusion US Xencor Yokogawa Electric Zavante Therapeutics Zosano Pharma

* New Members from March 2016 to May 2016

Biocom LifeLines Summer 2016

35


BIOCOM MEMBERSHIP CRO/CMO

Bavarian Nordic Behavioral Pharma Bend Research BioAtla BioBlocks BioDuro Bio-Edge Bioserv Corporation BTS Research CalChem Synthesis Cassia Cato Research Champions Oncology Charles River Laboratories ChemDiv ChemPartner Cleave Biosciences Clintec International Crown Bioscience San Diego Cytelligen Davos Chemical

Drug Delivery Experts eStudySite Evotec Exon BioSystems Explora BioLabs Genea Biocells Global Blood Therapeutics GRAM Laboratories Hamamatsu Pharma Research* Hamari Chemical San Diego Research Center HD Biosciences Huntingdon Life Sciences IMS Health Integrium Clinical Research inVentiv Health Clinical IriSys JadeBio KaloBios Pharmaceuticals Mediconomics MicroConstants

Molecular Imaging MPI Research MS Clinical Services My Chem LLC Naeja Pharmaceutical Neuroservice Neuro-Sys Nexus Biosciences Ora Pacific Rim Pathology PacificGMP PharPoint Research PharmaDirections Pharmatek Laboratories PrimaPharma Profil Institute for Clinical Research PSI CRO Puracyp Qoolabs Quadrants Scientific Reveal Biosciences

Rho Robarts Clinical Trials SAFC Pharma SGS Life Sciences Sherpa Clinical Packaging Spaulding Clinical Research Starfish Medical SureClinical* SynteractHCR Therapeutics, Inc. Tioga Research Toxikon Toyota Tsusho Corporation* Triligent International Ultimate Labs VIRAPUR Wax-It Histology Services WuXi AppTec Zensun USA Zyagen

MEDIC AL DEVICE & DIAGNOSTIC

CeloNova BioSciences Ceterix ChromaCode* Click Diagnostics Cliniqa Corporation CombiMatrix Compellon Confirm Biosciences Critical Diagnostics CTK Biotech CVAC Systems Cytori Therapeutics DCN Diagnostics DermTech International DexCom Diadexus Dorsa Vi USA Elixir Medical Corporation Ellipse Technologies Emerge Diagnostics Endologix Enigma Diagnostics Entra Health Epic Sciences Epitope Diagnostics

Fallbrook Engineering FemCap FP Complete* Fortimedix USA GenomeDx Biosciences GenWay Biotech GIMDx Glaukos Corporation Glysens Heart Metabolics USA* Hitachi Chemical Research Center Ichor Medical Systems Ignyta ImpediMed ImThera Medical Inari Medical Inceptus Medical INOVA Diagnostics Interpreta Interventional Spine Invivoscribe Technologies Ionian Technologies Ivantis KFx Medical Lumira

MARDX Diagnostics Mass Spec Lab Medipacs Micell Technologies Millennium Health Minerva Surgical Namiki Precision of California* Nano Imaging Services Nanomedical Diagnostics NuFACE Omniome OncoSec Medical Organovo Parallel 6 Profusa Prometheus Laboratories Qico Qualigen Quidel Quinn Medical ReCor Medical Renew Medical ReShape Medical REVA Medical ReVision Optics

Roka Bioscience SeaSpine Orthopedics Sequenom Sequent Medical Sienna Labs Signal Genetics Simplify Medical Sirigen Solekai Systems Sonendo SpectraScience Spinal Elements Spine Ovations Statrad LLC Suneva Medical Sysmex America Tandem Diabetes Targeson Tokai Medical Products* Tristan Technologies Trovagene Uptake Medical Vention Medical Xtant Medical

NON-PROFIT

Kaiser Permanente La Jolla Bioengineering Institute La Jolla Institute for Allergy & Immunology Lawrence Family Jewish Community Center Los Angeles Biomedical Research Institute Lowy Medical Research Institute MiraCosta College Biotech Program Mt. San Jacinto College PhRMA Point Loma Nazarene University PRISM Rady School of Management, UCSD Salk Institute for Biological Studies San Diego Biomedical Research Institute

San Diego Blood Bank San Diego Clinical and Translational Research Institute, UCSD San Diego Community College District San Diego County Water Authority San Diego Employers Association San Diego Regional Chamber of Commerce San Diego Regional Economic Development Corp. San Diego Supercomputer Center (UCSD) San Diego Workforce Partnership Sanford-Burnham Medical Research Institute Scottish Development International Scripps Health Scripps Research Institute

SDSU, Graduate & Research Affairs* Torrey Pines Institute for Molecular Studies UC San Diego Extension UC San Diego Office of Innovation & Commercialization UCI’s Office of Research UCSD, Department of Bioengineering UCSD, Office of Advancement UCSD School of Medicine UK Trade & Investment University of San Diego USC Stevens Center for Innovation* Sanford-Burnham Medical Research Institute Scottish Development International Scripps Health Scripps Research Institute

SDSU, School of Business Administration* The BioIndustry Association Torrey Pines Institute for Molecular Studies UC San Diego Extension UC San Diego Office of Innovation & Commercialization UCI’s Office of Research UCSD, Department of Bioengineering UCSD School of Medicine UK Trade & Investment University of San Diego

3DT Holdings Abbiotec ABL Absorption Systems Accelagen Accenture Accelerated RD* Accugent Laboratories Acurian Advantar Laboratories Advin Biotech Agility Clinical Alkahest Alliance Protein Laboratories A&M Biomedical American Peptide Company AnaBios Annova Chem Aptuit Atheln

Acon Laboratories Aethlon Medical Alphatec Spine AltheaDx Amydis Diagnostics Applied Proteomics Astute Medical Axonics Modulation Technologies Banyan Biomarkers BeneChill Biocept BioDx Biological Dynamics Biomerica Biospacific bioTheranostics Bio Trace Medical Breathe Technologies Bruin Biometrics Burl Concepts Cell Idx

American Cancer Society, Border Sierra Region Calibr California Baptist University, College of Engineering California State University, San Marcos CIRM City Of Murietta CONNECT Consulate of Canada CSU, CSUPERB Program CSU, Los Angeles Human BioMolecular Research Institute Institute of Engineering in Medicine ISM San Diego J. Craig Venter Institute

36

Biocom LifeLines Summer 2016


INDIVIDUAL Antoinette Azevedo Bernard King Carol Gallagher Dan Burgess* Decky Goodrich Donna Janson Elliot Parks Jack Florio John Kavanagh Mike Van Horn Peter Preuss Richard Ledford Stan Kim Tom Murphy

KEY PROVIDER Covington & Burling* Cushman & Wakefield Foley & Lardner Qualcomm San Diego Gas & Electric

PROVIDER 2Connect Accelrys AER Travel Alliant Insurance AMN Healthcare Assay Depot Azzur Group*

Bank of America Bionest Partners BioSurplus Biotech Primer Biotechnical Services BioTix Blue Sky Broadcast Brizzey Burger Construction* Caliber Associates California Commercial Security Cambridge Research Biochemicals Cardinal Health Regulatory Sciences Catalyst eClinical* CBRE Central Pharma Contract Packaging Chubb Group of Insurance Companies Clinigen Healthcare Coastal Payroll Services Coffee Ambassador CohnReznick LLP Controlled Contamination Services Corning CORT CryoPort CSM Cymer Dentons Domain Associates DPR Construction Echo Laboratories* Elsevier Elwood Professional* Ferguson Pape Baldwin Architects

Fisher & Phillips Forward Ventures Fragomen, Del Rey, Bernsen & Loewy French Biobeach Global Source Ventures Grande Colonial Green Charge Networks Gunderson Dettmer Hartl Team- Private Banking & Investment Group- Merrill Lynch Haworth HCP Life Science Estates H.G. Fenton Company HUB International* Hyatt Regency La Jolla at Aventine Innovative Lease Services J.T. MacMillan Photography Jackson & Blanc HVAC Contractors Jones Lang LaSalle Kilroy Realty Knobbe, Martens, Olson & Bear Leadership Edge Leverage Concierge Life Science IT Lonza AG Managed Laboratory Services Mayer Hoffman McCann Medline Industries Michael Ehrenfeld Company Morrison & Foerster Objective Capital Partners Occupational Services Orion International Patent Office Oxford Finance

PR Newswire Prevost Construction Procopio, Cory, Hargreaves & Savitch Project Management Advisors Prudential Cleanroom Services Quintiles Contract Sales Organization* Retirement DNA Retrophin* Sartorius Savills Studley ScaleMatrix* SecureDocs Scient Federal Credit Union Scripps Center for Dental Care Sharp Business Systems Sheppard Mullin Richter & Hampton Shred San Diego Signature Analytics Silicon Valley Bank Sofinnova Ventures Sonceboz Corporation Speid & Associates Springer Science & Business Media Square 1 Bank SteelWave Stradling Yocca Carlson & Rauth Surplus Solutions Technical Safety Services Telepacific Communications The HealthEd Group Time Warner Cable Toft Group Executive Seach TriNet Troutman Sanders

TUV SUD America Unanet Unifirst United Parcel Service (UPS) Vault Bioventures VDP Direct Veolia Virdisgroup Watson Biolab USA WCCT Global Zayo Group*

* New Members from March 2016 to May 2016

HELPING INNOVATION THRIVE. With more than 300 legal professionals operating in over 25 countries, our Life Sciences practice handles some of the most complex, high-profile life sciences transactions, litigation matters, patents and regulatory issues on behalf of biopharmaceutical and medical device companies. For five years in a row, DLA Piper has earned the No. 1 ranking globally for overall deal volume in Mergermarketâ&#x20AC;&#x2122;s league tables, and Global Corporate Venturing magazine has named us the 2015 Law Firm of the Year in Corporate Venture. We have built our reputation by providing cutting-edge solutions that help innovation thrive.

www.dlapiper.com

Lisa A. Haile, 4365 Executive Drive, Suite 1100, San Diego, CA 92121 | DLA Piper LLP (US) | Attorney Advertising


10996 Torreyana Rd, Suite 200 San Diego, CA 92121-3021 www.Biocom.org Please send a change of address or subscription request to info@biocom.org.

3-DAY EVENT

MICROBIAL FERMENTATION WORKSHOP August 17-19, 2016 // La Jolla, CA This 3­day workshop is designed to provide a deep dive into bioreactor principles and bioprocess development. You will be equipped with the fundamental knowledge and practical skills needed to design, develop optimize, control, scale­up, analyze, and troubleshoot your fermentation processes. Five interactive case studies allow attendees to practice what they have learned. The “Fermentation Firing Line” provides a lively, open ended forum for attendees to pose questions to the instructional team on any fermentation­related subject.

Plus...

Site V isit an Ferme d nter D emo a t W

hite La

bs

SPEAKERS James Golden, Ph.D. Professor, Molecular Biology UC San Diego Jeff Lievense, Ph.D. Senior Engineering Fellow Genomatica

Michael Japs Director, Commercial Technology Dev. Genomatica Jon Hansen, Ph.D. VP Science and Technology Heliae

Group Discounts Available! For more information and to register: (858) 534­9353 unexbio@ucsd.edu extension.ucsd.edu/lifesciences

Tim Dodge, M.S. Senior Staff Scientist Dupont Steve Kennedy, MBA SVP Technical Operations Histogenics

“Microbial fermentation is really big, and it’s growing really fast. It will change our world over the next 50 years." ­ Jeff Lievense, Ph.D., Sr. Engineering Fellow, Genomatica

LifeLines Summer 2016  
LifeLines Summer 2016